Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load

Lancet. 1997 May 24;349(9064):1517. doi: 10.1016/S0140-6736(97)24021-3.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Cohort Studies
  • Double-Blind Method
  • Drug Combinations
  • Drug Resistance, Microbial / genetics
  • HIV Infections / drug therapy
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Mutation / genetics
  • Placebos
  • Quinoxalines
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Viral Load
  • Viremia / virology
  • Virus Replication / drug effects

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • Drug Combinations
  • Placebos
  • Quinoxalines
  • Reverse Transcriptase Inhibitors
  • HBY 097